The natural antigens of group 2 CD1 are not well-characterized, but a synthetic glycolipid, alpha-galactosylceramide, originally isolated from a compound found in a marine sponge, has strong biologic activity.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Epitope||HLA||Vector Type||Inquiry & Datasheet|
|TCR-C162Z||Chimeric anti-mCD1d-α-GalCer T cell receptor, pCDTCR1||Chimeric||Lentiviral|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-TCR-C278||Lenti-mCD1d-α-GalCer T cell receptor Viral Particle||CMV||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE